The Specimen Resource Core will use existing infrastructure to address the broad needs of translational? studies in two skin cancers that are not met by current specimen acquisition, diagnosis and distribution? shared facilities. The core will engage in collecting, storing and distribution of a wide range of specimens and? reagents, specimen analysis and reagent verification. In addition, it will develop new approaches for? multiplex specimen analysis, DNA and RNA extraction and amplification, comprehensive database systems,? and computational analysis. More specifically, the core will: a) build on and extend the current repertoire of? specimens for translational studies in skin cancers, including normal skin, melanocytic lesions, melanoma,? BCC, serum and circulating lymphocytes, ensuring their proper storage, annotation, and timely distribution to? SPORE investigators; b) coordinate the construction of nevi/melanoma tissue microarrays and test/cell? arrays; c) validate antibodies and TMA results; d) establish and maintain a central database program of? essential pathological, clinical, epidemiological, follow-up information and basic research data that will be? integrated with the bioinformatics/statistics core; e) provide special services such as the analysis of? specimens for clinical trials, mutations, chromatin modification, and responses to novel drugs; f) maintain? and distribute verified reagents (antibodies, oligonucleotides, DNA, RNA, plasmids, proteins) needed for? tumor and cell analyses; g) spearhead the development of new approaches for specimen diagnosis, such as? multiplex analysis of markers, isolation and amplification procedures for mRNA and DNA from scarce? specimens; and h) establish links with shared facilities at Yale and similar resources in other institutions,? including other SPOREs. This core will interact extensively with the Bioinformatics, Clinical Trial Office,? Immunology, Critical Technologies, and Genetics shared facilities of the Yale Comprehensive Cancer? Center. The services of the Specimen Resource Core will enhance the efficient operation of the translational? studies in the SPORE in a cost-effective manner, and expedite the application of discoveries at the bench to? clinical practice, and clinical results to basic research.
| Ferrucci, Leah M; Cartmel, Brenda; Clare, Rachel A et al. (2018) Cross-sectional assessment of ultraviolet radiation-related behaviors among young people after a diagnosis of melanoma or basal cell carcinoma. J Am Acad Dermatol 79:149-152 |
| Arbesman, Joshua; Ravichandran, Sairekha; Funchain, Pauline et al. (2018) Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations. Pigment Cell Melanoma Res 31:529-533 |
| Perry, Curtis J; Muñoz-Rojas, Andrés R; Meeth, Katrina M et al. (2018) Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J Exp Med 215:877-893 |
| Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther : |
| Sulkowski, Parker L; Scanlon, Susan E; Oeck, Sebastian et al. (2018) PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF. Mol Cancer Res 16:1241-1254 |
| Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131 |
| Krauthammer, Michael (2018) Unraveling the etiology of primary malignant melanoma of the esophagus. J Thorac Dis 10:S1074-S1075 |
| Das, Rituparna; Bar, Noffar; Ferreira, Michelle et al. (2018) Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 128:715-720 |
| Weed, Jason; Gibson, Juliet; Lewis, Julia et al. (2017) FISH Panel for Leukemic CTCL. J Invest Dermatol 137:751-753 |
| Zhang, Yanchang; Cartmel, Brenda; Choy, Courtney C et al. (2017) Body mass index, height and early-onset basal cell carcinoma in a case-control study. Cancer Epidemiol 46:66-72 |
Showing the most recent 10 out of 172 publications
